Product
Dendritic Cell Tumor Cell Lysate Vaccine
1 clinical trial
1 indication
Indication
GlioblastomaClinical trial
Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive GlioblastomaStatus: Recruiting, Estimated PCD: 2024-08-01